Keyuan Pharmaceutical released its 2026 interim report. The company's total operating revenue was 331 million yuan, net profit attributable to the parent company was 64.6921 million yuan, and net cash inflow from operating activities was 42.2572 million yuan. The company's latest asset-liability ratio was 25.17%, up 2.98 percentage points from the previous quarter and up 11.32 percentage points from the same period last year. Gross margin was 55.71%, down 1.89 percentage points from the previous quarter. ROE was 4.53%, and diluted earnings per share was 0.60 yuan. Total asset turnover was 0.18 times, and inventory turnover was 1.07 times. The number of shareholders was 8,900, and the shareholding ratio of the top ten shareholders was 62.48%.
Shandong Keyuan Pharmaceutical Co. Ltd. ACompany reports net profit of 64.6921 million yuan in interim report.
